Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 3Plasma cell 1Myeloid 1Classical hematology 1CNS 1

Conditions

Lymphoma 5Central Nervous System Neoplasms 4Neuroblastoma 2Meningeal Carcinomatosis 2Brain Neoplasms 2Vasculitis, Central Nervous System 1Thrombocytopenia 1Stiff-Person Syndrome 1Rhabdoid Tumor 1Recurrence 1Rasmussen subacute encephalitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Opsoclonus-Myoclonus Syndrome 1Neurotoxicity Syndromes 1Neuromyelitis Optica 1Neurofibromatosis 1 1Myasthenia Gravis 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia 1Lambert-Eaton Myasthenic Syndrome 1Intraocular Lymphoma 1HIV Infections 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1Autoimmune Diseases of the Nervous System 1

Interventions

sodium thiosulfate 3Filgrastim 3Carboplatin 3etoposide phosphate 2Cyclophosphamide 2pegfilgrastim 1Vincristine 1Trastuzumab 1Temozolomide 1Rituximab 1Procarbazine 1Methotrexate 1Mannitol 1Lomustine 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Genetic Therapy 1Etoposide 1Cytarabine 1Cefixime 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Cytarabine × CNS × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡